Keyword: Kymriah (tisagenlecleucel)
French biotech Cellectis is building facilities in Paris and the U.S. to produce allogeneic CAR-T treatments.
Pharmas often face scrutiny on price hikes for old drugs, but now investors are asking Novartis about high prices for groundbreaking new drugs.
Payer coverage is key to Novartis’ plan to get Kymriah going, and the company is going to be getting some more of that.
Two senators have introduced a bill designed to encourage deals that would allow insurers to spread payments for expensive therapies over time.
Novartis figures biopharma companies both large and small will need to embrace alternative payment models for pricey gene and cell therapies.
The cell and gene therapy fields remain in early stages, but Novartis' CEO sees a big future. He's working to position Novartis ahead of the pack.
Novartis continues to wrestle with manufacturing issues for Kymriah, a problem that is hampering Kymriah sales.
Novartis is weighing an insurance method often associated with natural disasters to help win coverage for its next-generation cell and gene therapies.
Gilead and Novartis are working to ramp up launches of their CAR-T drugs, and both companies are hoping longer-term data will help do the trick.